- Home
- BGLC vs VYNE Comparison
BGLC vs VYNE Comparison
Compare BGLC & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- VYNE
- Stock Information
- Founded
- BGLC 2017
- VYNE 2003
- Country
- BGLC Malaysia
- VYNE United States
- Employees
- BGLC N/A
- VYNE N/A
- Industry
- BGLC Medical Specialities
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- VYNE Health Care
- Exchange
- BGLC Nasdaq
- VYNE Nasdaq
- Market Cap
- BGLC 10.4M
- VYNE 9.6M
- IPO Year
- BGLC N/A
- VYNE 2018
- Fundamental
- Price
- BGLC $5.40
- VYNE $0.35
- Analyst Decision
- BGLC
- VYNE Buy
- Analyst Count
- BGLC 0
- VYNE 2
- Target Price
- BGLC N/A
- VYNE $8.00
- AVG Volume (30 Days)
- BGLC 99.3K
- VYNE 2.8M
- Earning Date
- BGLC 11-14-2025
- VYNE 11-10-2025
- Dividend Yield
- BGLC N/A
- VYNE N/A
- EPS Growth
- BGLC N/A
- VYNE N/A
- EPS
- BGLC N/A
- VYNE N/A
- Revenue
- BGLC $9,551,559.00
- VYNE $476,000.00
- Revenue This Year
- BGLC N/A
- VYNE N/A
- Revenue Next Year
- BGLC N/A
- VYNE N/A
- P/E Ratio
- BGLC N/A
- VYNE N/A
- Revenue Growth
- BGLC 4.01
- VYNE N/A
- 52 Week Low
- BGLC $2.01
- VYNE $0.28
- 52 Week High
- BGLC $15.60
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- BGLC 52.88
- VYNE 43.56
- Support Level
- BGLC $5.00
- VYNE $0.33
- Resistance Level
- BGLC $5.37
- VYNE $0.39
- Average True Range (ATR)
- BGLC 0.34
- VYNE 0.03
- MACD
- BGLC 0.02
- VYNE -0.00
- Stochastic Oscillator
- BGLC 61.14
- VYNE 14.70
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.